Evaluating the value of genomic diagnostics: Implications for clinical practice and public policy

Advances in Health Economics and Health Services Research

Volumn 19, Issue , 2008, Pages 191-206

  Issa, Amalia M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG INDUSTRY; ECONOMICS; GENETIC MARKER; GENETIC PREDISPOSITION; HEALTH CARE POLICY; HUMAN; MEDICAL GENETICS; METHODOLOGY; PHARMACOGENETICS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

COST-BENEFIT ANALYSIS; DRUG INDUSTRY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETICS, MEDICAL; HEALTH POLICY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 53749085611     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0731-2199(08)19009-4     Document Type: Review

References (49)

1. Albanell J., and Baselga J. Trastuzumab, a humanized anti-HER 2 monoclonal antibody, for the treatment for breast cancer. Drugs Today 35 12 (1999) 931-946
2. Barratt A., Irwing L., Glasziou P., Cumming R.G., Raffle A., Hicks N., et al. Users' guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-based medicine working group. Journal of the American Medical Association 281 21 (1999) 2029-2034
3. Burczynski M.E., Oestreicher J.L., Cahilly M.J., Mounts D.P., Whitley M.Z., Speicher L.A., and Trepicchio W.L. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Current Molecular Medicine 5 1 (2005) 83-102
4. Busse R., Orvain J., Velasco M., Perleth M., Drummond M., Gurtner F., et al. Best practice in undertaking and reporting health technology assessments. Working group 4 report. International Journal of Technology Assessment in Health Care 18 2 (2002) 361-422
5. Cohen M.H., Moses M.L., and Pazdur R. Gleevec for the treatment of chronic myelogenous leukemia: US Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. The Oncologist 7 5 (2002) 390-392
6. DAKO. (1998). HercepTest Package Insert. DAKO Corp., Carpineteria, California. Available from: http://www.dakocytomation.com/
7. Dauzat M., Laroche J.P., Deklunder G., Ayoub J., Quere I., Lopez F.M., et al. Diagnosis of acute lower limb deep venous thrombosis with ultrasound: Trends and controversies. Journal of Clinical Ultrasound 25 7 (1997) 343-358
8. Deininger M.W. Basic science going clinical: Molecularly targeted therapy of chronic myelogenous leukemia. Journal of Cancer Research and Clinical Oncology 130 2 (2004) 59-72
9. De Leon J., Susce M.T., and Murray-Carmichael E. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Molecular Diagnosis & Therapy 10 3 (2006) 135-151
10. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. The New England Journal of Medicine 348 6 (2003) 538-549
11. Evans W.E., and Relling M.K. Moving towards individualized medicine with pharmacogenomics. Nature 429 6990 (2004) 464-468
12. Food and Drug Administration. (1998). Letter of Approval. Available from: www.fda.gov/cder/approval/index
13. Food and Drug Administration Department of Health and Human Services. Part 809 - In Vitro Diagnostic Products for Human Use. 21CFR809.3, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=809.3
14. Freudenberg-Hua Y., Freudenberg J., Winantea J., Kluck N., Cichon S., Bruss M., Propping P., and Nothen M.M. Systematic investigation of genetic variability in 111 human genes-implications for studying variable drug response. Pharmacogenomics Journal 5 3 (2005) 183-192
15. Fryback D.G., and Thornbury J.R. The efficacy of diagnostic imaging. Medical Decision Making 11 2 (1991) 88-94
16. Genentech, Inc. (2006). Annual report. Available from: http://www.gene.com/gene/ir/financials/annual-reports/2006/2006annualreport.pdf
17. Genentech, Inc. (2008). Drug prescribing information: Herceptin (Trastuzumab). Available from: http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf
18. Grillo-Lopez A.J., Hedrick E., Rashford M., and Benyunes M. Rituximab: Ongoing and future clinical development. Seminars in Oncology 29 1 Suppl. 2 (2002) 105-112
19. Grosse S.D., and Khoury M.J. What is the clinical utility of genetic testing?. Genetics in Medicine 8 7 (2006) 448-450
20. Guyatt G.H., Tugwell P.X., Feeny D.H., Haynes R.B., and Drummond M. A framework for clinical evaluation of diagnostic technologies. Canadian Medical Association Journal 134 6 (1986) 587-594
21. Halkin A., Reichman J., Schwaber M., Paltiel O., and Brezis M. Likelihood ratios: Getting diagnostic testing into perspective. QJM: An International Journal of Medicine 91 4 (1998) 247-258
22. Hammock L., Lewis M., Phillips C., and Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Human Pathology 34 10 (2003) 1043-1047
23. Issa A.M. Perspectives in pharmacogenomic profiling in the drug development process. Nature Review Drug Discovery 1 4 (2002) 300-308
24. Issa A.M. Clinical applications of pharmacogenomics to adverse drug reactions. Expert Review of Clinical Pharmacology 1 2 (2008) 251-260
25. Khoury M.J. Genetics and genomics in practice: The continuum from genetic disease to genetic information in health and disease. Genetics in Medicine 5 4 (2003) 261-268
26. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., and Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 9 5 (2004) 442-473
27. Lewin Group. (2005). The value of diagnostics innovation, adoption and diffusion into health care, pp. 1-230. Available from: http://www.socalbio.org/pdfs/thevalueofdiagnostics.pdf
28. Lord S.J., Irwig L., and Simes R.J. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?. Annals of Internal Medicine 144 11 (2006) 850-855
29. Luftner D., Henschke P., Kafka A., Anagnostopoulos I., Wiechen K., Geppert R., Stein H., Wernecke K.D., Kreienberg R., and Possinger K. Discordant results obtained for different methods of HER-2/neu testing in breast cancer - a question of standardization, automation and timing. The International Journal of Biological Markers 19 1 (2004) 1-13
30. Oncor. (1998). Oncor INFORM HER-2/neu Gene detection system: Procedure and interpretation guide. Ventana Medical Systems, Tucson, AZ. Available from: http://www.ventanamed.com
31. PathVysion Her-2 Package Insert. (1998). Vysis, Inc. Downers Grove, III. Available from: http://www.vysis.com/PathVysionHER@DNAProbeKit_35922
32. Phillips K.A., and Van Bebber S.L. Cost-effectiveness of pharmacogenomic interventions: A systematic review of the literature. Pharmacogenomics 5 8 (2004) 1139-1149
33. Phillips K.A., Veenstra D., Van Bebber S.L., and Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 4 3 (2003) 231-239
34. Phillips K.A., Veenstra D.L., Ramsey, S.D., Van Bebber S.L., and Sakowski J. Genetic testing and pharmacogenomics: Issues for determining the impact to health care delivery and costs. The American Journal of Managed Care 10 7 Pt 1 (2004) 425-432
35. Robertson J.A., Brody B., Buchanan A., Kahn J., and McPherson E. Pharmacogenetic challenges for the health care system. Health Affairs 21 4 (2002) 155-167
36. Ross J.S., and Ginsburg G.S. The integration of molecular diagnostics with therapeutics. American Journal of Clinical Pathology 119 1 (2003) 26-36
37. Sanderson S., Zimmern R., Kroese M., Higgins J., et al. How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genetics in Medicine 7 7 (2005) 495-500
38. Shah R., Darne B., Atar D., Abadie E., Adams K.F., and Zannad F. Pharmacogenomics in cardiovascular clinical trials. Fundamental and Clinical Pharmacology 18 6 (2004) 705-708
39. Stallings S.C., Huss D., Finkelstein N., Crown W.H., Witt W.P., Maguire J., Hiller A.J., Sinskey A.J., and Ginsburg G.S. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics 7 6 (2006) 853-862
40. Sullivan S.D., and Weiss K.B. Health economics of asthma and rhinitis II. Assessing the value of interventions. The Journal of Allergy and Clinical Immunology 107 2 (2001) 203-210
41. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: A report on principles. Annals of Internal Medicine 123 1 (1995) 61-70
42. Tatsioni A., Zarin D.A., Aronson N., Samson D.J., et al. Challenges in systematic reviews of diagnostic technologies. Annals of Internal Medicine 142 12 Pt 2 (2005) 1048-1055
43. United States Food and Drug Administration. (2007). New labeling information for warfarin (marketed as Coumadin). August 16, 2007. Available from: http://www.fda.gov/cder/drug/infopage/warfarin/default.htm
44. Van den Akker-van Marle M.E., Gurwitz D., Detmar S.B., et al. Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7 5 (2006) 783-792
45. Varian H.R. Intermediate microeconomics. A modern approach (1993), W. W. Norton and Company, New York
46. Veenstra D.L., Higashi M.K., and Phillips K.A. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmaceutical Sciences 2 3 (2000) E29: 1-11
47. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Steart S.J., and Press M. Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER 2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 3 (2002) 719-726
48. Wajapeyee N., and Somasundaram K. Pharmacogenomics in breast cancer: Current trends and future directions. Current Opinion in Molecular Therapeutics 6 3 (2004) 296-301
49. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., and Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. Journal of Clinical Pathology 53 5 (2000) 374-381